• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

壳聚糖包裹 mimic miR-155-5p 和拮抗剂 miR-324-5p 对卵巢癌 SKOV3 的影响。

The Effects of Combination of Mimic miR-155-5p and Antagonist miR-324-5p Encapsulated Chitosan in Ovarian Cancer SKOV3.

机构信息

Study Program of Biotechnology, Graduate School, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2603-2608. doi: 10.31557/APJCP.2020.21.9.2603.

DOI:10.31557/APJCP.2020.21.9.2603
PMID:32986358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779436/
Abstract

OBJECTIVE

Ovarian cancer is a malignant tumor that attacks reproductive organs of women. MicroRNA is known to have an involvement in the prognosis of ovarian cancer. One of them is miR-155-5p which is down regulated and miR-324-5p which is up regulated. Chitosan is used as microRNA delivery system. The aims of this study is to find out the effects of combination microRNA encapsulated chitosan in cell line SKOV3.

METHODS

Cell line SKOV3 obtained from Stem Cell and Cancer Institute (Kalbe). Mimic miR-155-5p and Antagonist miR-324-5p formulated with chitosan. Total RNA was extracted from nine samples (three as control and six as treatment), and prepared for cDNA synthesis. Expression of RNA and mRNA target was measured using q-PCR Biorad CFX96 C.100 and Gen Ex 7 software. Statistics analysis was measured using SPSS 16.0.

RESULTS

The administration of combination microRNA encapsulated with chitosan affect the expression of miR-155-5p and miR-324-5p endogen (p <0.05). The expression of mRNA target HIF1α and GLI1 was down regulated after treatment. The correlation between expression of microRNA and mRNA target was strongly (p <0.05).

CONCLUSION

This study successfully presented effects of combination of mimic miR-155-5p and antagonist miR-324-5p encapsulated chitosan which be considered as a potential therapy targets for ovarium cancer.

摘要

目的

卵巢癌是一种恶性肿瘤，攻击女性生殖器官。miRNA 已知参与卵巢癌的预后。其中之一是下调的 miR-155-5p 和上调的 miR-324-5p。壳聚糖可用作 miRNA 递送系统。本研究的目的是研究组合 miR-155-5p 和 miR-324-5p 封装壳聚糖在 SKOV3 细胞系中的作用。

方法

从 Stem Cell and Cancer Institute (Kalbe) 获得 SKOV3 细胞系。用壳聚糖制备 mimic miR-155-5p 和 Antagonist miR-324-5p。从 9 个样本（3 个作为对照，6 个作为处理）中提取总 RNA，并制备 cDNA 合成。使用 Biorad CFX96 C.100 和 Gen Ex 7 软件通过 q-PCR 测量 RNA 和 mRNA 靶标表达。使用 SPSS 16.0 进行统计分析。

结果

壳聚糖包封的组合 microRNA 的给药影响内源性 miR-155-5p 和 miR-324-5p 的表达（p <0.05）。治疗后，mRNA 靶标 HIF1α 和 GLI1 的表达下调。miRNA 表达与 mRNA 靶标之间存在强相关性（p <0.05）。

结论

本研究成功展示了 mimic miR-155-5p 和 antagonist miR-324-5p 封装壳聚糖的组合的影响，可作为卵巢癌的潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/c63ce7398801/APJCP-21-2603-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/d59398b2b792/APJCP-21-2603-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/d9fddff100f9/APJCP-21-2603-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/42fd9111238f/APJCP-21-2603-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/ab2988cd3a8d/APJCP-21-2603-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/c63ce7398801/APJCP-21-2603-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/d59398b2b792/APJCP-21-2603-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/d9fddff100f9/APJCP-21-2603-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/42fd9111238f/APJCP-21-2603-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/ab2988cd3a8d/APJCP-21-2603-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b1c/7779436/c63ce7398801/APJCP-21-2603-g005.jpg

相似文献

1
The Effects of Combination of Mimic miR-155-5p and Antagonist miR-324-5p Encapsulated Chitosan in Ovarian Cancer SKOV3.壳聚糖包裹 mimic miR-155-5p 和拮抗剂 miR-324-5p 对卵巢癌 SKOV3 的影响。
Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2603-2608. doi: 10.31557/APJCP.2020.21.9.2603.
2
The effects of miR-140-5p on the biological characteristics of ovarian cancer cells through the Wnt signaling pathway.miR-140-5p 通过 Wnt 信号通路对卵巢癌细胞生物学特性的影响。
Adv Clin Exp Med. 2020 Jul;29(7):777-784. doi: 10.17219/acem/121933.
3
RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.RhoC是微小RNA-93-5P在上皮性卵巢癌发生发展过程中的主要靶点。
Mol Cancer. 2015 Feb 4;14(1):31. doi: 10.1186/s12943-015-0304-6.
4
Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.通过靶向C-Jun恢复卵巢癌中的miR-139-5p可逆转顺铂耐药性。
Cell Physiol Biochem. 2018;51(1):129-141. doi: 10.1159/000495169. Epub 2018 Nov 15.
5
miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.微小RNA-339-5p通过靶向NACC1和BCL6抑制卵巢癌细胞系的迁移和侵袭。
Tumour Biol. 2016 Apr;37(4):5203-11. doi: 10.1007/s13277-015-4390-2. Epub 2015 Nov 9.
6
Tumor-suppressor miRNA-27b-5p regulates the growth and metastatic behaviors of ovarian carcinoma cells by targeting CXCL1.抑癌 miRNA-27b-5p 通过靶向 CXCL1 调节卵巢癌细胞的生长和转移行为。
J Ovarian Res. 2020 Aug 11;13(1):92. doi: 10.1186/s13048-020-00697-6.
7
Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p.长链非编码 RNA DUXAP8 通过靶向 miR-590-5p 调控卵巢癌细胞的增殖和凋亡。
Hum Cell. 2020 Oct;33(4):1240-1251. doi: 10.1007/s13577-020-00398-8. Epub 2020 Aug 4.
8
Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.Lnc00908 通过调控 microRNA-495-5p 促进卵巢癌的发展。
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1388-1396. doi: 10.26355/eurrev_201902_17095.
9
Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1.Linc00161 通过海绵吸附 microRNA-128 并调节 MAPK1 来调节卵巢癌的耐药性。
Mol Carcinog. 2019 Apr;58(4):577-587. doi: 10.1002/mc.22952. Epub 2019 Jan 22.
10
MicroRNA-155-5p Diminishes in Vitro Ovarian Cancer Cell Viability by Targeting HIF1α Expression.微小RNA-155-5p通过靶向缺氧诱导因子1α表达降低体外卵巢癌细胞活力。
Adv Pharm Bull. 2020 Sep;10(4):630-637. doi: 10.34172/apb.2020.076. Epub 2020 Aug 9.

引用本文的文献

1
Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment.未来的诊疗策略：新兴的卵巢癌生物标志物以弥合诊断与治疗之间的差距。
Front Drug Deliv. 2024 Feb 1;4:1339936. doi: 10.3389/fddev.2024.1339936. eCollection 2024.
2
CircZNF609/miR-324-5p/voltage-dependent anion channel 1 axis promotes malignant progression of ovarian cancer cells.环状锌指蛋白609/微小RNA-324-5p/电压依赖性阴离子通道1轴促进卵巢癌细胞的恶性进展。
iScience. 2024 Aug 31;27(11):110861. doi: 10.1016/j.isci.2024.110861. eCollection 2024 Nov 15.
3
MicroRNA‑mediated approaches in ovarian cancer therapy: A comprehensive systematic review.

本文引用的文献

1
Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.使用miRNA靶向治疗组合增强对肿瘤发生的抑制作用。
Front Pharmacol. 2019 May 16;10:488. doi: 10.3389/fphar.2019.00488. eCollection 2019.
2
MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities.卵巢癌中的 microRNA：生物学、发病机制和治疗机会。
Int J Environ Res Public Health. 2019 Apr 29;16(9):1510. doi: 10.3390/ijerph16091510.
3
Endometrial thickness still presents a best reference to predict endometrial cancer.
微小RNA介导的卵巢癌治疗方法：一项全面的系统综述。
Oncol Lett. 2024 Aug 12;28(4):491. doi: 10.3892/ol.2024.14624. eCollection 2024 Oct.
4
Anti-inflammatory activities of flavonoid derivates.黄酮类衍生物的抗炎活性。
ADMET DMPK. 2023 Jul 26;11(3):331-359. doi: 10.5599/admet.1918. eCollection 2023.
5
Chitosan-Based Nanoparticles for Nucleic Acid Delivery: Technological Aspects, Applications, and Future Perspectives.用于核酸递送的壳聚糖基纳米颗粒：技术层面、应用及未来展望
Pharmaceutics. 2023 Jun 29;15(7):1849. doi: 10.3390/pharmaceutics15071849.
6
Chitosan Based MicroRNA Nanocarriers.基于壳聚糖的微小RNA纳米载体
Pharmaceuticals (Basel). 2022 Aug 23;15(9):1036. doi: 10.3390/ph15091036.
7
A review on the role of miRNA-324 in various diseases.关于miRNA - 324在多种疾病中作用的综述。
Front Genet. 2022 Aug 10;13:950162. doi: 10.3389/fgene.2022.950162. eCollection 2022.
8
Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.肿瘤微环境中 microRNAs 的治疗靶向。
Int J Mol Sci. 2021 Feb 23;22(4):2210. doi: 10.3390/ijms22042210.
子宫内膜厚度仍然是预测子宫内膜癌的最佳参考指标。
Taiwan J Obstet Gynecol. 2016 Feb;55(1):148-9. doi: 10.1016/j.tjog.2015.07.003.
4
Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells.用于向MCF-7乳腺癌细胞进行基因递送的壳聚糖-微小RNA纳米复合物的物理化学和生物学特性
Sci Rep. 2015 Sep 1;5:13567. doi: 10.1038/srep13567.
5
In vivo delivery of miRNAs for cancer therapy: challenges and strategies.用于癌症治疗的微小RNA的体内递送：挑战与策略
Adv Drug Deliv Rev. 2015 Jan;81:128-41. doi: 10.1016/j.addr.2014.05.009. Epub 2014 May 22.
6
MiR-324-5p inhibits proliferation of glioma by target regulation of GLI1.微小RNA-324-5p通过对GLI1的靶向调控抑制神经胶质瘤的增殖。
Eur Rev Med Pharmacol Sci. 2014;18(6):828-32.
7
Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.透明质酸-壳聚糖纳米粒共载 miR-34a 和多柔比星治疗三阴性乳腺癌。
Biomaterials. 2014 May;35(14):4333-44. doi: 10.1016/j.biomaterials.2014.02.006. Epub 2014 Feb 22.
8
Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.Glioma-associated oncogene homolog 1（gli1）在晚期浆液性卵巢癌中的表达与不良的总生存期相关。
PLoS One. 2013;8(3):e60145. doi: 10.1371/journal.pone.0060145. Epub 2013 Mar 28.
9
On measuring miRNAs after transient transfection of mimics or antisense inhibitors.关于测量转染 mimic 或反义抑制剂后 miRNA 的表达。
PLoS One. 2013;8(1):e55214. doi: 10.1371/journal.pone.0055214. Epub 2013 Jan 24.
10
Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells.小脑神经元祖细胞和肿瘤细胞中微小RNA对刺猬信号通路的协同调控
EMBO J. 2008 Oct 8;27(19):2616-27. doi: 10.1038/emboj.2008.172. Epub 2008 Aug 28.